Cargando…

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer

OBJECTIVE: 18F-ﬂuorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) can provide prognostic information, especially 18F-FDG uptake has been proven to be a predictor for the prognosis of various tumors. Nevertheless, the prognosis of other PET parameters in the metastati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yi, Liu, Cheng, Wang, Bibo, Hu, Xichun, Gong, Chengcheng, Zhao, Yannan, Xie, Yizhao, Zhang, Yingjian, Song, Shaoli, Yang, Zhongyi, Wang, Biyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123971/ https://www.ncbi.nlm.nih.gov/pubmed/34007206 http://dx.doi.org/10.2147/IJGM.S293998

Ejemplares similares

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Zhao, Yannan, et al.
Publicado: (2018)

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET
por: Xie, Yizhao, et al.
Publicado: (2022)

Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
por: Ma, Guang, et al.
Publicado: (2023)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
por: Gong, Chengcheng, et al.
Publicado: (2017)

(18)F-FLT and (18)F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results
por: Qi, Shi, et al.
Publicado: (2017)

Prognostic Impact of Pretreatment 2-[(18)F]-FDG PET/CT Parameters in Primary Gastric DLBCL
por: Albano, Domenico, et al.
Publicado: (2021)

Establishment and validation of a nomogram with intratumoral heterogeneity derived from (18)F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
por: Gu, Bingxin, et al.
Publicado: (2020)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
por: Gong, Chengcheng, et al.
Publicado: (2022)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Xie, Yizhao, et al.
Publicado: (2021)

Prognostic value of pretreatment (18)F-FDG PET-CT for nasopharyngeal carcinoma patients
por: Huang, Yecai, et al.
Publicado: (2017)

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
por: You, Shuhui, et al.
Publicado: (2023)

Prognostic value of pretreatment (18)F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma
por: Jo, In Young, et al.
Publicado: (2015)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

The prognostic value of (18)F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients
por: Liu, Jun, et al.
Publicado: (2022)

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2019)

Machine learning based on clinico-biological features integrated (18)F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung
por: Ren, Caiyue, et al.
Publicado: (2020)

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
por: Zhao, Yannan, et al.
Publicado: (2021)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

The Added Value of (68)Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG–Negative Findings
por: Gu, Bingxin, et al.
Publicado: (2022)

The Role of Pretreatment (18)F-FDG PET/CT for Early Prediction of Neoadjuvant Chemotherapy Response in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yao, Jijin, et al.
Publicado: (2021)

Radiomic analysis for predicting prognosis of colorectal cancer from preoperative (18)F-FDG PET/CT
por: Lv, Lilang, et al.
Publicado: (2022)

Metastatic bilateral adrenal sarcomatoid carcinoma: Evaluation by (18)F-FDG PET/CT
por: Rachh, Swati, et al.
Publicado: (2022)

Mesenteric Panniculitis Appears as Metastatic Disease on (18)F-FDG-PET/CT Scan
por: Ekmekçioğlu, Özgül, et al.
Publicado: (2022)

Impact of pretreatment second look (18)FDG-PET/CT on stage and treatment changes in head and neck cancer
por: Elicin, Olgun, et al.
Publicado: (2021)

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients
por: Nappi, Antonio, et al.
Publicado: (2015)

Prognostic value of pretreatment (18)F-FDG PET/CT metabolic parameters in esophageal high-grade neuroendocrine carcinoma: A bicenter retrospective study
por: Hou, Guozhu, et al.
Publicado: (2023)

Precision of quantitative parameters of (18)F-FDG PET/CT in a rabbit VX2 tumor model
por: Guo, Bin, et al.
Publicado: (2023)

(18)F-FDG PET/CT radiomic analysis for classifying and predicting microvascular invasion in hepatocellular carcinoma and intrahepatic cholangiocarcinoma
por: Jiang, Chunjuan, et al.
Publicado: (2022)

Preoperative (18)F-FDG PET/CT radiomics analysis for predicting HER2 expression and prognosis in gastric cancer
por: Liu, Qiufang, et al.
Publicado: (2023)

Predicting EGFR mutation subtypes in lung adenocarcinoma using (18)F-FDG PET/CT radiomic features
por: Liu, Qiufang, et al.
Publicado: (2020)

The Role of the Metabolic Parameters of (18)F-FDG PET/CT in Patients With Locally Advanced Cervical Cancer
por: Wang, Dunhuang, et al.
Publicado: (2021)

(68)Ga-FAPI and (18)F-FDG PET/CT Images in a Patient With Extrapulmonary Tuberculosis Mimicking Malignant Tumor
por: Gu, Bingxin, et al.
Publicado: (2020)

(18)F-FDG PET/CT Imaging In Oncology
por: Almuhaideb, Ahmad, et al.
Publicado: (2011)

Scar Sarcoidosis on (18)F-FDG PET/CT
por: Arora, Saurabh, et al.
Publicado: (2019)

18F-FDG PET/CT and COVID-19
por: Joob, Beuy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ok0jp820qb6a465jdh5a1p5l0q